|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 600 Massachusetts Ave, NW |
Address2 | SUITE 300 |
| City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kendra Tunstall |
Date | 7/19/2024 3:20:53 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues related to FDA and HHS program funding for the FY24 Labor, HHS, Education and Related Agencies, and FY24 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
Strategic National Stockpile (SNS) Funding and Oversight
Funding for FDA e-labeling rule implementation
Patient access to Part B medicines during the COVID-19 public health emergency
Issues related to 340B program oversight
Support for increased investments to address antimicrobial resistance.
Deficit reduction, reconciliation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Vanessa |
Gannon |
|
|
|
Thomas |
Stoll |
|
|
|
Ravi |
Upadhyay |
|
|
|
Jill |
Shotzberger |
|
|
|
David |
Cooling |
|
|
|
Caleb |
Graff |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Intellectual property and process patent issues
Patent litigation reforms
PTAB and IPR processes
Section 101 Reform
Domestic and international compulsory licensing issues
March-in Rights
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to the 340B Drug Discount Program
Issues relating to drug pricing
Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives.
Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars.
General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to healthcare legislation
Patient access to Part B medicines during the COVID-19 public health emergency
Issues related to health equity, diversity, and inclusion in clinical trials
Issues related to advanced development and procurement of medical countermeasures (MCMs)
Issues related to patient assistance and access
Issues relating to privacy and securing the data of and personal information of consumers
Issues relating to medical research data
Issues relating to screening and diagnostics
Issues related to public health preparedness and response
Issues related to awareness about diabetic eye diseases in minority populations
Issues related to public health preparedness.
Issues related to access to drugs for minority communities
Issues related to healthcare education and screening
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Jill |
Shotzberger |
|
|
|
Thomas |
Stoll |
|
|
|
Elise |
Conner |
|
|
|
Matt |
Sulkala |
|
|
|
Vanessa |
Gannon |
|
|
|
Dan |
Neves |
|
|
|
David |
Cooling |
|
|
|
Ravi |
Upadhyay |
|
|
|
Caleb |
Graff |
|
|
|
Estevan |
Santana |
|
|
|
Valerie |
Reynolds |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to Medicare and Medicaid coverage and reimbursement
Issues related to the 340B Drug Discount Program
Issues related to drug pricing
Medicare reimbursement for biosimilars
Issues related to CMMI
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Vanessa |
Gannon |
|
|
|
Jill |
Shotzberger |
|
|
|
Ravi |
Upadhyay |
|
|
|
Caleb |
Graff |
|
|
|
Estevan |
Santana |
|
|
|
Valerie |
Reynolds |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to R&D tax deductions and expense amortization
Issues related to international taxation, including foreign-derived intangible income and interest deductions
Issues related to supply chain incentives
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
|
Matthew |
Sulkala |
|
|
|
Ravi |
Upadhyay |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver
Issues related to compulsory licensing of foreign patents
Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Issues related to public health protection including influenza development and preparedness
Issues related to antimicrobial and antiviral research and product development
Issues related to novel coronavirus and COVID-19 research and product development
Issues related to drug development including PDUFA and Cures 2.0
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Gannon |
|
|
|
Elise |
Conner |
|
|
|
David |
Burt |
|
|
|
Dan |
Neves |
|
|
|
David |
Cooling |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Drug pricing issues
Prescription Drug User Fee Act reauthorization
Issues related to prescription drug value
Issues related to the 340B Drug Discount Program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Elise |
Conner |
|
|
|
Vanessa |
Gannon |
|
|
|
Ravi |
Upadhyay |
|
|
|
Jill |
Shotzberger |
|
|
|
David |
Cooling |
|
|
|
Matthew |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
Issues related to pharmaceutical supply chains
Issues related to reporting on location of origin of pharmaceutical products
Issues related to drug shortages
Issues related to pharmaceutical manufacturing
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Stoll |
|
|
|
Dan |
Neves |
|
|
|
Jill |
Shotzberger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
Issues relating to limits and restrictions on the immigration of high skilled workers
Issues relating to the immigration of medical researchers
17. House(s) of Congress and Federal agencies Check if None
Homeland Security - Dept of (DHS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
|
Matt |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |